The Pharmaceutical Market: Serbia

Abstract

Serbia has overcome many of the political and economic problems it faced following the break-up of the former Yugoslavia. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Serbia has overcome many of the political and economic problems it faced following the break-up of the former Yugoslavia. Although challenges still exist for the Serbian government, a number of developments have assisted Serbia in strengthening its economy and political stability. The government is Western-leaning and actively seeking membership of the EU, NATO and the World Trade Organisation. Serbia declared its independence from Montenegro in June 2006. Serbia has an estimated population of 7.4 million, of which 15.0% are aged 65 years or over.

The healthcare system remains in a poor condition. It is over-resourced in terms of medical personnel and much of its equipment is outdated. Nevertheless, improvements are gradually taking place with foreign investment, such as loans from the European Agency for Reconstruction, helping to refurbish or develop new health centres. The private healthcare sector is slowly expanding, although currently it only serves a wealthy minority.

Serbia has a small pharmaceutical industry, although this is expected to expand as manufacturers begin to operate in accordance with GMP standards, making their products more appealing to Western Europe. Fluctuations in the value of exports have been replaced by a steady increase that began in 2001. In January 2003, the Icelandic company Actavis purchased a 70% stake in Zdravlje, the third largest pharmaceutical company in Serbia. This has opened up new markets for products made by Zdravlje and will strengthen the generics manufacturing base already established in Serbia.

MARKET OUTLOOK

• Current market size
• Unique 5-year market projections
• Market outlook
• Market structure
  • Includes data on imports and exports for raw materials and finished products
• Market developments
  • Recent and impending developments with respect to key issues such as regulation, health facilities and government policy
• Key national data projections

BACKGROUND DATA

• Population data, including growth trends and age structure
• Demographic indicators detailing principal causes of death and morbidity

HEALTHCARE SYSTEM

• Health expenditure
• Hospital services
  • Hospital data such as beds by type, specialty, patient admissions and occupancy
• Outpatient care
• Medical personnel
  • Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists ACCESSING

ACCESSING THE PHARMACEUTICAL MARKET

• Regulatory environment
• Patent protection & intellectual property rights
• Pricing & reimbursement
• Distribution channels
• Domestic production

CONTACT DETAILS

• For healthcare organisations

Compelling reasons to buy this Espicom market report

Espicom is a leading provider of market and company information for business. In addition to this analysis, Espicom provides detailed management reports on over 60 established and emerging pharmaceutical markets around the world.

• Includes - FREE - three quarterly updated outlook reports on the Serbian pharma market
• Unique and original market forecasts
• Insightful interpretation of market trends and developments
• Fantastic value - no-one else produces such quality data so cost effectively
• Over 25 years continuous pharmaceutical market experience
• A team of full-time researchers and analysts
• Unbeatable access to primary sources
• Independent and impartial
• Formats to suit every distribution need and budget